231 related articles for article (PubMed ID: 29284740)
21. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
22. A common ancestry for BAP1 and Uch37 regulators.
Sanchez-Pulido L; Kong L; Ponting CP
Bioinformatics; 2012 Aug; 28(15):1953-6. PubMed ID: 22645167
[TBL] [Abstract][Full Text] [Related]
23. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
24. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
[TBL] [Abstract][Full Text] [Related]
25. Roles of the BAP1 Tumor Suppressor in Cell Metabolism.
Han A; Purwin TJ; Aplin AE
Cancer Res; 2021 Jun; 81(11):2807-2814. PubMed ID: 33446574
[TBL] [Abstract][Full Text] [Related]
26. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
[TBL] [Abstract][Full Text] [Related]
27. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression.
Yu H; Mashtalir N; Daou S; Hammond-Martel I; Ross J; Sui G; Hart GW; Rauscher FJ; Drobetsky E; Milot E; Shi Y; Affar el B
Mol Cell Biol; 2010 Nov; 30(21):5071-85. PubMed ID: 20805357
[TBL] [Abstract][Full Text] [Related]
28. The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex.
Ji Z; Mohammed H; Webber A; Ridsdale J; Han N; Carroll JS; Sharrocks AD
Nucleic Acids Res; 2014 Jun; 42(10):6232-42. PubMed ID: 24748658
[TBL] [Abstract][Full Text] [Related]
29. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
Abdel-Wahab O; Dey A
Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis identifies novel binding partners of BAP1.
Baas R; J van der Wal F; Bleijerveld OB; van Attikum H; Sixma TK
PLoS One; 2021; 16(9):e0257688. PubMed ID: 34591877
[TBL] [Abstract][Full Text] [Related]
31. Tumours associated with BAP1 mutations.
Murali R; Wiesner T; Scolyer RA
Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
33. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Ventii KH; Devi NS; Friedrich KL; Chernova TA; Tighiouart M; Van Meir EG; Wilkinson KD
Cancer Res; 2008 Sep; 68(17):6953-62. PubMed ID: 18757409
[TBL] [Abstract][Full Text] [Related]
34. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
[TBL] [Abstract][Full Text] [Related]
35. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.
Masclef L; Ahmed O; Estavoyer B; Larrivée B; Labrecque N; Nijnik A; Affar EB
Cell Death Differ; 2021 Feb; 28(2):606-625. PubMed ID: 33462414
[TBL] [Abstract][Full Text] [Related]
36. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation.
Campagne A; Lee MK; Zielinski D; Michaud A; Le Corre S; Dingli F; Chen H; Shahidian LZ; Vassilev I; Servant N; Loew D; Pasmant E; Postel-Vinay S; Wassef M; Margueron R
Nat Commun; 2019 Jan; 10(1):348. PubMed ID: 30664650
[TBL] [Abstract][Full Text] [Related]
37. Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Fukuda T; Tsuruga T; Kuroda T; Nishikawa H; Ohta T
Curr Cancer Drug Targets; 2016; 16(2):101-9. PubMed ID: 26517537
[TBL] [Abstract][Full Text] [Related]
38. BAP1 in solid tumors.
Di Nunno V; Frega G; Santoni M; Gatto L; Fiorentino M; Montironi R; Battelli N; Brandi G; Massari F
Future Oncol; 2019 Jun; 15(18):2151-2162. PubMed ID: 31159579
[TBL] [Abstract][Full Text] [Related]
39. Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains.
Zhou ZR; Zhang YH; Liu S; Song AX; Hu HY
Biochem J; 2012 Jan; 441(1):143-9. PubMed ID: 21851340
[TBL] [Abstract][Full Text] [Related]
40. BAP1 loss defines a new class of renal cell carcinoma.
Peña-Llopis S; Vega-Rubín-de-Celis S; Liao A; Leng N; Pavía-Jiménez A; Wang S; Yamasaki T; Zhrebker L; Sivanand S; Spence P; Kinch L; Hambuch T; Jain S; Lotan Y; Margulis V; Sagalowsky AI; Summerour PB; Kabbani W; Wong SW; Grishin N; Laurent M; Xie XJ; Haudenschild CD; Ross MT; Bentley DR; Kapur P; Brugarolas J
Nat Genet; 2012 Jun; 44(7):751-9. PubMed ID: 22683710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
